Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid

Neurobiology of Aging

Volumn 30, Issue 7, 2009, Pages 1069-1077

  Strozyk, Dorothea ^a,b   Launer, Lenore J ^b   Adlard, Paul A ^c   Cherny, Robert A ^c   Tsatsanis, Andrew ^c   Volitakis, Irene ^c   Blennow, Kaj ^d   Petrovitch, Helen ^e   White, Lon R ^e   Bush, Ashley I ^c,f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid; Cerebrospinal fluid; Chromium; Copper; Iron; Manganese; Metalloproteinase; Zinc

Indexed keywords

ALUMINUM; AMYLOID BETA PROTEIN[1-42]; CHROMIUM; COPPER; IRON; MANGANESE; METALLOPROTEINASE; SELENIUM; ZINC;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; MALE; MOLECULAR INTERACTION; NEUROPATHOLOGY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ASIAN AMERICANS; BRAIN; BRAIN CHEMISTRY; CEREBROSPINAL FLUID; CHROMIUM; COHORT STUDIES; COPPER; HUMANS; IRON; MALE; MANGANESE; PEPTIDE FRAGMENTS; ZINC;

EID: 67349139416     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.10.012     Document Type: Article

References (43)

1. Andreasen N., Hesse C., Davidsson P., Wallin A., Minthon L., Winblad B., Vanderstichele H., Vanmechelen E., and Blennow K. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56 (1999) 673-680
2. Atwood C.S., Moir R.D., Huang X., Bacarra N.M.E., Scarpa R.C., Romano D.M., Hartshorn M.A., Tanzi R.E., and Bush A.I. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273 (1998) 12817-12826
3. Basun H., Forssell L.G., Wetterberg L., and Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J. Neural Transm. Park. Dis. Dement. Sect. 3 4 (1991) 231-258
4. Bateman R.J., Munsell L.Y., Morris J.C., Swarm R., Yarasheski K.E., and Holtzman D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12 7 (2006) 856-861
5. Brody D.L., and Holtzman D.M. Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp. Neurol. 197 2 (2006) 330-340
6. Brown A.M., Tummolo D.M., Rhodes K.J., Hofmann J.R., Jacobsen J.S., and Sonnenberg-Reines J. Selective aggregation of endogenous β-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc. J. Neurochem. 69 3 (1997) 1204-1212
7. Bush A.I. The metallobiology of Alzheimer's disease. TINS 26 4 (2003) 207-214
8. Bush A.I., Pettingell Jr. W.H., Paradis M.D., and Tanzi R.E. Modulation of Aβ adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. 269 (1994) 12152-12158
9. Bush A.I., Pettingell W.H., Multhaup G., Paradis M.D., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., and Tanzi R.E. Rapid induction of Alzheimer Aß amyloid formation by zinc. Science 265 (1994) 1464-1467
10. Bush A.I., Moir R.D., Rosenkranz K.M., and Tanzi R.E. Zinc and Alzheimer's disease. Science 268 (1995) 1921-1923
11. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., and Black R.A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273 43 (1998) 27765-27767
12. Cherny R.A., Legg J.T., McLean C.A., Fairlie D., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., and Bush A.I. Aqueous dissolution of Alzheimer's disease Aß amyloid deposits by biometal depletion. J. Biol. Chem. 274 (1999) 23223-23228
13. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y.-S., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., and Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
14. Dong J., Atwood C.S., Anderson V.E., Siedlak S.L., Smith M.A., Perry G., and Carey P.R. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42 10 (2003) 2768-2773
15. Du Y., Ni B., Glinn M., Dodel R.C., Bales K.R., Zhang Z., Hyslop P.A., and Paul S.M. Alpha2-Macroglobulin as Aβ-amyloid peptide-binding plasma protein. J. Neurochem. 69 1 (1997) 299-305
16. Flaten T.P. Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain Res. Bull. 55 2 (2001) 187-196
17. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5 3 (2006) 228-234
18. Huang X., Atwood C.S., Moir R.D., Hartshorn M.A., Vonsattel J.-P., Tanzi R.E., and Bush A.I. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 272 (1997) 26464-26470
19. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., and Bush A.I. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38 (1999) 7609-7616
20. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., and Bush A.I. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274 (1999) 37111-37116
21. Ibach B., Haen E., Marienhagen J., and Hajak G. Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report. Pharmacopsychiatry 38 4 (2005) 178-179
22. Lee J.-Y., Cole T.B., Palmiter R.D., Suh S.W., and Koh J.-Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99 11 (2002) 7705-7710
23. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., and Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158 1 (1998) 47-52
24. Maruyama M., Higuchi M., Takaki Y., Matsuba Y., Tanji H., Nemoto M., Tomita N., Matsui T., Iwata N., Mizukami H., Muramatsu S., Ozawa K., Saido T.C., Arai H., and Sasaki H. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann. Neurol. 57 6 (2005) 832-842
25. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., White A.R., Beyreuther K., Masters C.L., Bush A.I., and Li Q.-X. Overexpression of Alzheimer's disease β-amyloid opposes the age-dependent elevations of brain copper and iron levels. J. Biol. Chem. 277 47 (2002) 44670-44676
26. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., Masters C.L., Li Q.X., and Bush A.I. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J. Inorg. Biochem. 100 5-6 (2006) 952-962
27. McCullagh P., and Nelder J. Generalized Linear Models (1989), Chapman and Hall, London, UK
28. McLean C., Cherny R., Fraser F., Fuller S., Smith M., Beyreuther K., Bush A., and Masters C. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 6 (1999) 860-866
29. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., and Berg L. The Consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
30. Molina J.A., Jimenez-Jimenez F.J., Aguilar M.V., Meseguer I., Mateos-Vega C.J., Gonzalez-Munoz M.J., de Bustos F., Porta J., Orti-Pareja M., Zurdo M., Barrios E., and Martinez-Para M.C. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J. Neural Transm. 105 4-5 (1998) 479-488
31. 2. J. Biol. Chem. 277 (2002) 40302-40308
32. 2+ complexes in Alzheimer's disease. Aging Cell 5 (2006) 69-79
33. Petrovitch H., Nelson J., Snowdon D., Davis D.G., Ross G.W., Li C.Y., and White L. Microscope field size and the neuropathologic criteria for Alzheimer's disease. Neurology 49 4 (1997) 1175-1176
34. Petrovitch H., White L.R., Ross G.W., Steinhorn S.C., Li C.Y., Masaki K.H., Davis D.G., Nelson J., Hardman J., Curb J.D., Blanchette P.L., Launer L.J., Yano K., and Markesbery W.R. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 57 2 (2001) 226-234
35. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273 49 (1998) 32730-32738
36. Regland B., Lehmann W., Abedini I., Blennow K., Jonsson M., Karlsson I., Sjogren M., Wallin A., Xilinas M., and Gottfries C.G. Treatment of Alzheimer's disease with clioquinol. Dement. Geriatr. Cogn. Disord. 12 6 (2001) 408-414
37. Religa D., Strozyk D., Cherny R.A., Volitakis I., Haroutunian V., Winblad B., Naslund J., and Bush A.I. Elevated cortical zinc in Alzheimer disease. Neurology 67 1 (2006) 69-75
38. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R.A., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., and Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
39. Rottkamp C., Raina A., Zhu X., Gaier E., Bush A., Atwood C., Chevion M., Perry G., and Smith M. Redox-active iron mediates amyloid-β toxicity. Free Radic. Biol. Med. 30 (2001) 447-450
40. Schlief M.L., Craig A.M., and Gitlin J.D. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J. Neurosci. 25 1 (2005) 239-246
41. Strozyk D., Blennow K., White L.R., and Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 4 (2003) 652-656
42. White L., Petrovitch H., Ross G.W., Masaki K.H., Abbott R.D., Teng E.L., Rodriguez B.L., Blanchette P.L., Havlik R.J., Wergowske G., Chiu D., Foley D.J., Murdaugh C., and Curb J.D. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging Study. JAMA 276 12 (1996) 955-960
43. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., Hoke D.E., Holsinger R.M., Evin G., Cherny R.A., Hill A.F., Barnham K.J., Li Q.X., Bush A.I., and Masters C.L. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281 26 (2006) 17670-17680